- Previous Close
52.30 - Open
57.50 - Bid 57.50 x --
- Ask --
- Day's Range
57.50 - 57.50 - 52 Week Range
45.90 - 85.60 - Volume
186,292 - Avg. Volume
1,266,282 - Market Cap (intraday)
5.088B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-3.03 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, which include western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.
www.energenesis-biomedical.comRecent News: 6657.TW
View MorePerformance Overview: 6657.TW
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6657.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6657.TW
View MoreValuation Measures
Market Cap
4.63B
Enterprise Value
3.97B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
520.95
Price/Book (mrq)
6.26
Enterprise Value/Revenue
512.75
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.82%
Return on Equity (ttm)
-29.95%
Revenue (ttm)
7.75M
Net Income Avi to Common (ttm)
-231.08M
Diluted EPS (ttm)
-3.03
Balance Sheet and Cash Flow
Total Cash (mrq)
664.98M
Total Debt/Equity (mrq)
1.36%
Levered Free Cash Flow (ttm)
-110.26M